Tesamorelin is one of the few peptides that has actually been through the full FDA approval process — and it\’s getting increasing attention in the anti-aging and metabolic health communities. It\’s particularly powerful for reducing visceral fat: the dangerous fat stored around your internal organs. Here\’s what you need to know.
What Is Tesamorelin?
Tesamorelin is a synthetic analog of GHRH (growth hormone releasing hormone). Like CJC-1295, it works by stimulating your pituitary gland to produce more of your own growth hormone.
It was developed and approved specifically to treat HIV-associated lipodystrophy — a condition where patients accumulate excess visceral fat around the abdomen. The FDA approved it in 2010 under the brand name Egrifta.
Outside of this approved use, it has attracted significant interest in the research and longevity community for its potent effects on visceral fat reduction and metabolic health.
Why Is Visceral Fat So Important?
Not all fat is created equal. Visceral fat — the fat stored deep inside your abdomen around your organs — is significantly more dangerous than subcutaneous fat.
High visceral fat is associated with:
- → Increased risk of type 2 diabetes
- → Heart disease and stroke
- → Liver disease
- → Insulin resistance
- → Chronic inflammation
Visceral fat is notoriously resistant to diet and exercise alone — especially as people age and growth hormone levels naturally decline. This is where tesamorelin comes in.
What Are the Benefits?
Clinical trials of tesamorelin have demonstrated:
- → Significant reduction in visceral adipose tissue (VAT) — typically 15–20% reduction over 6 months
- → Improved triglyceride levels
- → Better insulin sensitivity
- → Improved body composition with reduced fat and maintained muscle
- → Enhanced sense of well-being and quality of life
- → Improvement in cognitive function in older adults (early research)
How Is It Used?
In its FDA-approved form, tesamorelin is administered as:
- → Daily subcutaneous injection — typically 2 mg per day
- → Injected into the abdomen
- → Ongoing treatment — effects diminish if stopped
⚠️ Important: Tesamorelin is FDA approved only for HIV-associated lipodystrophy. Off-label use should be supervised by a qualified physician.
Side Effects
Because tesamorelin works through your body\’s own GH system, side effects are generally milder than exogenous growth hormone:
- → Joint pain or stiffness
- → Fluid retention / edema
- → Muscle pain
- → Numbness or tingling
- → Injection site reactions
Quick Reference
| Factor | Details |
|---|---|
| Type | GHRH analog (synthetic) |
| Brand Name | Egrifta |
| FDA Status | Approved — HIV-associated lipodystrophy |
| Key Benefit | Visceral fat reduction (~15–20% in 6 months) |
| Dose | 2 mg/day subcutaneous injection |
| Best For | Visceral fat, metabolic health, anti-aging |
The Bottom Line
Tesamorelin is one of the most clinically validated peptides for fat loss — particularly visceral fat — backed by actual FDA approval and real human clinical trial data. If you\’re interested in a growth hormone-stimulating peptide with the strongest available evidence base, tesamorelin deserves serious attention.
// Where to Source
All suppliers listed below have been vetted by TalkPeps for COA transparency and product quality. Use the exclusive discount codes to save on your order.
TalkPeps may earn a commission on purchases at no extra cost to you. Research compounds only — not for human therapeutic use.